US FDA approved first biosimilar drug Mvasi/bevacizumab-awwb for the treatment of different kind of cancers. Mvasi is quite equal in efficacy to already present reference product Avastin (Genetech/Roche) which was approved by US FDA in 2004. Mvasi has same indications like the reference product Avastin (Genetech/Roche). Mvasi/bevacizumab-awwb major indications include colon cancer, non-small cell lung cancer, glioblastoma, ovarian cancer, breast cancer and renal cell carcinoma. US FDA approved this biosmilar drug on the basis of cost difference because biosimilars are expected to be cheaper but their safety profile, indications and adverse effects are quite similar to reference product.
Cancer is one of the leading cause of death across the globe. Some tumors are not metastatic and less dangerous as compared to other metastatic cancers. Each cancer might have different sign and symptoms as compared to other one but as a general some commonly observed symptoms of cancer are consistent weight loss, sweating during night time, bleeding, formation of lumps, changes in bowel movements. Some kind of viral infections may also lead to cancer if persist for a longer period of time.
Rigorous research is still on the way to find complete cure of cancer. Etiology of each cancer might be different but certain risk factors like genetic predisposition, exposure to radiations and chemicals, chronic viral infections, sedentary life style, obesity, smoking, alcoholism and environmental pollution play important role in its development.
Mvasi Side effects
Some commonly observed side effects during this drug therapy include
- Bleeding or hemorrhage
- Nasal cavity swelling
- Loss of protein through urine
- Changes in mouth taste
- Abdominal Discomfort
- Dryness of skin
- Excessive lacrimation
- Skin allergy
US FDA approved Mvasi for the treatment of Metastatic colorectal cancer in combination with other drugs or as second line therapy, non-squamous non-small cell lung cancer, glioblastoma in aggressive stage, metastatic renal cell carcinoma and cervical cancer.
Metastatic colorectal cancer
- 5 mg/kg IV every 2 weeks with bolus-IFL
- 10 mg/kg IV every 2 weeks with FOLFOX4
- 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks with
Non-squamous non-small cell lung cancer
- 15 mg/kg IV every 3 weeks with carboplatin/paclitaxel
- 10 mg/kg IV every 2 weeks
- 10 mg/kg IV every 2 weeks with interferon alfa Persistent, recurrent, or metastatic carcinoma of the cervix
- 15 mg/kg IV every 3 weeks with paclitaxel/cisplatin or paclitaxel/topotecan.